Results 81 to 90 of about 21,696 (215)

Practical management of myelofibrosis with ruxolitinib

, 2015
Treatment for the majority of patients with myelofibrosis is primarily based on symptom control as curative allogeneic stem cell transplantation is typically offered only to younger patients, especially those with poor prognosis disease.
Marlton, P., Ritchie, D, Stevenson, W., Dunlop, L.C., Ritchie, D., Ross, David M., Bird, Robert, Durrant, S, Ho, PJ, Tam, C., Ross, D. M., Bird, R, Ho, Joy, Ross, DM, Ross, D.M., Marlton, Paula V., Stevenson, W, Dunlop, L. C., Dunlop, LC, Ritchie, David, Dunlop, Lindsay C. (R18423), Tam, Constantine, Tam, C, Bird, R., Ho, P., Ho, P.J., Marlton, P, Bird, Robert J., Durrant, S., Durrant, Simon   +29 more
core   +1 more source

When Treatment Meets Natural History: Understanding Early Dermatitis‐Related Adverse Events in Systemic Atopic Dermatitis Trials

JEADV Clinical Practice, EarlyView.
ABSTRACT Biologics and Janus kinase (JAK) inhibitors have transformed the management of atopic dermatitis (AD), yet some patients experience early worsening of disease activity during treatment initiation. In clinical trials, these events are typically recorded as treatment‐emergent adverse events (TEAEs), most commonly coded as “atopic dermatitis”. We
Diego Ruiz Dasilva, Alondra Soto‐Gonzalez, Haya Alkiswani, Graham H. Litchman, Harrison Nguyen, Gil Yosipovitch, Firas George Hougeir, Matthew Zirwas, David Cotter, Brad Glick, E. James Song, Christopher G. Bunick, Neal Bhatia, Adam Friedman, Leon Kircik, Mona Shahriari, Peter Lio, James Del Rosso   +17 more
wiley   +1 more source

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor

, 2017
Palma Manduzio Department of Haematology and Oncology, Haematology With BMT, IRCCS, Casa Sollievo della Sofferenza, Foggia, Italy Abstract: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm classified according to the 2016 revision of World ...
Manduzio P
core  

Ruxolitinib in contemporary treatment of myelofibrosis

, 2018
Introduction: Myelofibrosis (MF) is a rare chronic Ph(-) myeloproliferative neoplasm that can man­ifest as a primary disease or secondary to polycythaemia vera or essential thrombocythaemia.
Koleva, Denica; Medical University of Varna, Kerim, Aylin; Medical University of Varna, Ahmed, Ahmed; Medical University of Varna, Milev, Emil; Medical University of Varna   +3 more
core   +1 more source

Real‐World Effectiveness and Safety of Topical Ruxolitinib in Adolescents With Vitiligo: A 52‐Week Retrospective Study

JEADV Clinical Practice, EarlyView.
Topical ruxolitinib 1.5% cream was assessed in 39 adolescents with non‐segmental vitiligo. Median T‐VASI fell at week 24 (n = 34) and week 52 (n = 18), with repigmentation most pronounced on the face: 55.6% reached F‐VASI50 at week 52. Few adverse events were recorded, all mild application‐site reactions in 4 of 39 patients.
L. Coronella, V. Picone, C. Costa, M. Napolitano   +3 more
wiley   +1 more source

Senotherapeutics for Knee Osteoarthritis

Medicinal Research Reviews, EarlyView.
ABSTRACT Osteoarthritis (OA) is a chronic disease that imposes a significant economic burden and deteriorates quality of life. Nevertheless, current therapeutic options for OA are limited to symptomatic remedies. As such, there is a high interest in novel methods for treating or preventing OA.
Ezgi Duman, Girish Pattappa, Patrick Pann, Stephan Reppenhagen, Maximilian Rudert, Peter Angele, Denitsa Docheva   +6 more
wiley   +1 more source

Precision immunomodulation for pediatric hemophagocytic lymphohistiocytosis in intensive care

Pediatric Investigation, EarlyView.
This review presents a bedside framework for recognizing pediatric hemophagocytic lymphohistiocytosis and cytokine storm, stabilizing organ dysfunction, identifying the underlying phenotype, selecting targeted immunomodulation, considering extracorporeal adjuncts, and reassessing response within 24–72 h. ABSTRACT Hemophagocytic lymphohistiocytosis (HLH)
Weerapong Lilitwat, Prakreeti Bhandari
wiley   +1 more source

Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations

, 2016
Sabine Blum,* Filipe Martins,* Lorenzo Alberio Service and Central Laboratory of Hematology, CHUV, University Hospital of Lausanne, Lausanne, Switzerland *These authors contributed equally to this work.
Martins F, Alberio L, Blum S
core  

Oxidative stress‐driven metabolic reprogramming defines two subtypes of cutaneous melanoma

VIEW, EarlyView.
Cutaneous melanoma exhibits substantial molecular heterogeneity, and metabolic reprogramming may contribute to differences in tumor behavior and treatment response. In this study, we integrated multi‐omics data from SKCM cohorts to identify two metabolism‐associated subtypes with distinct oxidative stress profiles, immune microenvironments, prognostic ...
Qikun Gao, Ziyi Liu, Ying Xu
wiley   +1 more source

Biomarkers Predictive of Immunotherapy Efficacy in Head and Neck Squamous Cell Carcinoma: Current Insights and Future Perspectives

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT With the approval of immunotherapies by regulatory bodies, head and neck squamous cell carcinoma (HNSCC) treatment has been revolutionized, and anti‐programmed cell death‐1 (anti‐PD‐1) agents are now the standard for platinum‐resistant recurrent/metastatic HNSCC.
Xiao‐Tong Yan, Zhao‐Hong An, Chang‐Ming An   +2 more
wiley   +1 more source